Executive Summary

Hyperlipidemia treatment in 2026 is best understood as a layered risk-management field rather than a single therapeutic category. Statins and ezetimibe remain foundational, but the practical frontier now includes monoclonal antibodies, twice-yearly or quarterly RNA-based therapies, newer oral non-statins, rare-disease triglyceride agents, and early approaches that attempt durable target silencing or gene editing.

The most important strategic distinction is not simply approved versus investigational. It is whether a therapy lowers a lipid marker, reduces cardiovascular outcomes, treats a genetically defined rare disease, or supports a specific population that is difficult to manage with conventional treatment. That distinction shapes evidence generation, labeling, payer positioning, and clinical sequencing.